Wuhan Univ. J. Nat. Sci.
Volume 27, Number 2, April 2022
|Page(s)||177 - 184|
|Published online||20 May 2022|
CLC number: Q819
Antitumor Response of Anti-B7-H3 CAR-T Cells with Humanized scFv in Solid Tumors
School of Biological Science and Medical Engineering, Southeast University, Nanjing
210096, Jiangsu, China
2 Zhangda Hospital, School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China
3 Jiangsu Yinfeng Biological Technology Co. Ltd, Nanjing 210014, Jiangsu, China
We prepared a humanized alternative B7-H3 CAR (B7-H3-haCAR-T) targeting B7-H3 which contained the humanized singl-chain varinlde fragment (scFv) from humanized 8H9 Monoclonal Antibody (hu8H9mAb). The antitumor effects of B7-H3-haCAR-T cells were evaluated in B7-H3 overexpressed tumor cells (in vitro) and B7-H3 xenograft models (in vivo). The specific tumour killing ability of B7-H3-haCAR-T in overexpressing B7-H3 tumour cells was verified by cytotoxicity and ELISA tests. In addition, B7-H3 haCAR-T cells were also noted to suppress the tumour growth remarkably well in the xenograft murine models, and the survival time in the haCAR-T cell treatment group was appreciably longer than that in the control group. The specific recognition and highly efficient tumoricidal behavior of B7-H3 haCAR-T provide a basis for future clinical studies with humanized scFv-transduced CAR-T cells targeting solid tumors.
Key words: humanization / single-chain variable fragment (scFv) / B7-H3 / haCAR-T / solid tumor
Biography: SI Ke, male, Ph.D. candidate, research direction: tumor immunotherapy, chimeric antigen receptor T-cell immunotherapy. E-mail: firstname.lastname@example.org
Foundation item: Supported by the National Natural Science Foundation of China (81671807) , the Key Research & Developement Program of Jiangsu Province (BE2020777) , Fundamental Research Funds for the Central Universities (2242018K3DN05, 2242021k10004)
© Wuhan University 2022
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.